Philips gets FDA clearance for Rembra platform to boost fast, precise CT imaging in cancer care.

Royal Philips received FDA 510(k) clearance for its Rembra platform, including Rembra CT, Rembra RT, and Areta RT systems, designed to enhance speed, efficiency, and precision in CT imaging and radiation therapy planning. This approval supports high-throughput imaging in critical care and cancer treatment, enabling up to 270 exams per day and improving workflow connectivity from diagnosis to therapy. The platform's large 85 cm bore and advanced imaging capabilities help clinicians make timely, accurate decisions, advancing personalized cancer care. Philips aims to expand access to high-quality imaging and streamline cancer treatment planning with this unified CT ecosystem.